|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
Checkmate Pharmaceuticals (2022)
|
|
gptkbp:awarded
|
gptkb:award
gptkb:Scrip_Award
|
|
gptkbp:CEO
|
gptkb:Leonard_Schleifer
|
|
gptkbp:collaboratedWith
|
gptkb:Bayer
gptkb:Sanofi
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:COVID-19Treatment
|
gptkb:REGEN-COV
|
|
gptkbp:focus
|
ophthalmology
immuno-oncology
rare diseases
inflammatory diseases
monoclonal antibodies
genetic medicines
|
|
gptkbp:foundedBy
|
gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer
|
|
gptkbp:foundedYear
|
1988
|
|
gptkbp:hasResearchCenter
|
gptkb:Rensselaer,_New_York
gptkb:Tarrytown,_New_York
|
|
gptkbp:headquartersLocation
|
gptkb:Tarrytown,_New_York,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Regeneron
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:memberOf
|
gptkb:Biotechnology_Innovation_Organization
|
|
gptkbp:netIncome
|
$4.2 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:EYLEA
gptkb:Libtayo
gptkb:REGEN-COV
gptkb:Dupixent
gptkb:Praluent
|
|
gptkbp:numberOfEmployees
|
~11,800
|
|
gptkbp:patent
|
biologic drugs
|
|
gptkbp:philanthropy
|
gptkb:Regeneron_Science_Talent_Search
|
|
gptkbp:president
|
gptkb:George_Yancopoulos
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:revenue
|
$13.1 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:S&P_500
|
|
gptkbp:stockSymbol
|
gptkb:REGN
|
|
gptkbp:subsidiary
|
gptkb:Regeneron_Pharmaceuticals_Ireland
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_REGN
|
|
gptkbp:website
|
https://www.regeneron.com/
|
|
gptkbp:bfsParent
|
gptkb:BioNTech
|
|
gptkbp:bfsLayer
|
5
|